alleen voor onderzoeksdoeleinden
Cat.nr.: S1244
Chemische structuur
| Gerelateerde doelwitten | EGFR VEGFR FGFR PDGFR c-Met Src MEK CSF-1R HER2 FLT3 |
|---|---|
| Overig c-Kit Inhibitoren | Masitinib Sitravatinib (MGCD516) OSI-930 PDGFR inhibitor 1 AZD3229 ISCK03 Masitinib mesylate Bezuclastinib Elenestinib phosphate M4205(IDRX-42) |
| Cellijnen | Assaytype | Concentratie | Incubatietijd | Formulering | Activiteitsbeschrijving | PMID |
|---|---|---|---|---|---|---|
| GIST | Function assay | Inhibition of AXL in human GIST cells, IC50<1μM | 26555154 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| Caco-2 | Function assay | 48 hrs | Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging, IC50=0.02μM | ChEMBL | ||
| Caco-2 | Function assay | 48 hrs | Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay, CC50=0.06μM | ChEMBL | ||
| GIST882 | Function assay | 4 days | Inhibition of c-kit gain of function mutant in human GIST882 cells measured after 4 days by sulforhodamine B assay, IC50=1.6μM | ChEMBL | ||
| GIST882 | Function assay | 96 hrs | Inhibition of c-kit gain of function mutant in human GIST882 cells after 96 hrs by Cell-Titer Glo luciferase assay, IC50=1.6μM | ChEMBL | ||
| MIAPaCa2 | Function assay | 4 days | Inhibition of PDGFRA in human MIAPaCa2 cells measured after 4 days by sulforhodamine B assay, IC50=2.1μM | ChEMBL | ||
| PANC1 | Function assay | 4 days | Inhibition of PDGFRA in human PANC1 cells measured after 4 days by sulforhodamine B assay, IC50=3μM | ChEMBL | ||
| SF-767 | Cytotoxicity assay | 1 uM | 24 hrs | Cytotoxicity against human SF-767 cells assessed as cell death at 1 uM after 24 hrs by MTS assay | ChEMBL | |
| SF-767 | Cytotoxicity assay | 1 uM | 24 hrs | Cytotoxicity against human SF-767 cells assessed as cell death at 1 uM in presence of 800Gy ionizing radiation after 24 hrs by MTS assay | ChEMBL | |
| SBcl2 | Antitumor assay | 5 days | Antitumor activity against human SBcl2 cells xenografted in ip dosed athymic nude mouse assessed as reduction in tumor growth administered as qd for 5 days | ChEMBL | ||
| HT-29 | Function assay | Suppression of ionizing radiation-induced Rad51 expression in human HT-29 cells pretreated with compound followed by ionizing radiation by Western blot analysis | ChEMBL | |||
| Klik om meer experimentele gegevens over cellijnen te bekijken | ||||||
| Molecuulgewicht | 447.51 | Formule | C23H21N5O3S |
Opslag (vanaf de datum van ontvangst) | |
|---|---|---|---|---|---|
| CAS-nr. | 850879-09-3 | SDF downloaden | Opslag van stamoplossingen |
|
|
| Synoniemen | HPK 56 | Smiles | C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6 | ||
|
In vitro |
DMSO
: 32 mg/mL
(71.5 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Stap 1: Voer onderstaande informatie in (Aanbevolen: een extra dier om rekening te houden met verlies tijdens het experiment)
Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in de sectie oplosbaarheid.)
Berekeningsresultaten:
Werkconcentratie: mg/ml;
Methode voor het bereiden van DMSO-moedervloeistof: mg geneesmiddel vooropgelost in μL DMSO ( Concentratie moedervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de batch van het geneesmiddel overschrijdt. )
Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toeμL PEG300, mengen en verhelderen, daarna toevoegenμL Tween 80, mengen en verhelderen, daarna toevoegen μL ddH2O, mengen en verhelderen.
Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toe μL Maïsolie, mengen en verhelderen.
Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysieke methoden zoals vortexen, ultrasoon of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.
| Targets/IC50/Ki |
c-Met
RAD51
c-RET
c-Kit (D816H)
10 nM
PDGFRα (V561D)
40 nM
FLT3 (D835Y)
81 nM
|
|---|---|
| In vitro |
The hydrochloride salt of Amuvatinib (MP-470) inhibits several mutants of c-Kit, including c-KitD816V, c-KitD816H, c-KitV560G, and c-KitV654A, as well as a Flt3 mutant (Flt3D835Y) and two PDGFRα mutants (PDGFRαV561D and PDGFRαD842V), with IC50 of 10 nM to 8.4 μM. It also binds to and inhibits several c-Kit mutants, including c-KitK642E, c-KitD816V, and c-KitK642E/D816V. This compound potently inhibits the proliferation of OVCAR-3, A549, NCI-H647, DMS-153, and DMS-114 cells, with IC50 of 0.9 μM–7.86 μM. It also inhibits c-Kit and PDGFRα, with IC50 values of 31 μM and 27 μM, respectively. It demonstrates potent cytotoxicity against MiaPaCa-2, PANC-1, and GIST882 cells, with IC50 of 1.6 μM to 3.0 μM. In MDA-MB-231 cells, it (1 μM) inhibits tyrosine phosphorylation of AXL. In LNCaP and PC-3, but not DU145 cells, it exhibits cytotoxicity with IC50 of 4 μM and 8 μM, respectively, and induces apoptosis at 10 μM. In LNCaP cells, it (10 μM) elicits G1 arrest and decreases phosphorylation of Akt and ERK1/2. In SF767 cells, it (10 μM) inhibits c-Met phosphorylation and sensitizes cells to radiation. In combination with radiation, it (10 μM) inhibits glycogen synthase kinase (GSK)3β activity, induces apoptosis, and disrupts the repair of dsDNA breaks probably through suppression of Rad51. |
| Kinase Assay |
Kinase-inhibitieassay van c-Kit en PDGFRα
|
|
Voor het testen van de remmende activiteit tegen c-Kit en PDGFRα worden enzymen geïncubeerd met variërende concentraties Amuvatinib (MP-470) en radiogelabeld γ-32P-ATP. Na 30 minuten worden de reactiemengsels geëlektroforeseerd op een acrylamidegel en wordt autofosforylering, gekwantificeerd door de hoeveelheid radioactiviteit die in het enzym is opgenomen, bepaald.
|
|
| In vivo |
In mice xenograft models of HT-29, A549, and SB-CL2 cells, Amuvatinib (MP-470) (10 mg/kg–75 mg/kg via i.p. or 50 mg/kg–200 mg/kg via p.o.) inhibits tumor growth. In mice bearing LNCaP xenograft, this compound (20 mg/kg) combined with Erlotinib significantly induces tumor growth inhibition (TGI). |
Referenties |
|
| Methoden | Biomarkers | Afbeeldingen | PMID |
|---|---|---|---|
| Growth inhibition assay | Cell viability |
|
24950457 |
| Western blot | p-AXL / AXL / p-AKT / AKT / ERK / Rad51 |
|
24950457 |
(gegevens van https://clinicaltrials.gov, bijgewerkt op 2024-05-22)
| NCT-nummer | Werving | Aandoeningen | Sponsor/medewerkers | Startdatum | Fasen |
|---|---|---|---|---|---|
| NCT01357395 | Completed | Small Cell Lung Carcinoma |
Astex Pharmaceuticals Inc. |
May 2011 | Phase 2 |